New drug combo aims to boost immune attack on Hard-to-Treat cancers

NCT ID NCT02671435

Ongoing Disease control Sponsor: MedImmune LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests two immunotherapy drugs, durvalumab and monalizumab, in about 383 adults with advanced solid tumors, including colorectal cancer. The goal is to see if the combination is safe and can shrink tumors. Some participants also receive standard chemotherapy or other targeted drugs. The trial is active but no longer recruiting new participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: durvalumab and monalizumab (immunotherapy drugs given by IV)
What this could lead to: If this combination works, it could offer a new treatment option for people with advanced solid tumors that have not responded to standard therapies.
What could go wrong: This is an early-phase trial, so the drugs may not shrink tumors or improve survival. Side effects from immune system activation can be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Locations

Research Site

Birmingham, Alabama, 35233, United States
Research Site

Scottsdale, Arizona, 85258, United States
Research Site

Duarte, California, 91010, United States
Research Site

La Jolla, California, 92093, United States
Research Site

Los Angeles, California, 90089, United States
Research Site

Sacramento, California, 95817, United States
Research Site

Santa Monica, California, 90404, United States
Research Site

Aurora, Colorado, 80045, United States
Research Site

Tampa, Florida, 33612, United States
Research Site

Chicago, Illinois, 60611, United States
Research Site

Baltimore, Maryland, 21231, United States
Research Site

Boston, Massachusetts, 02215, United States
Research Site

Detroit, Michigan, 48202, United States
Research Site

New Brunswick, New Jersey, 08903, United States
Research Site

New Hyde Park, New York, 11042, United States
Research Site

New York, New York, 10065, United States
Research Site

The Bronx, New York, 10461, United States
Research Site

Providence, Rhode Island, 02903, United States
Research Site

Nashville, Tennessee, 37203, United States
Research Site

Dallas, Texas, 75235, United States
Research Site

San Antonio, Texas, 78229, United States
Research Site

Salt Lake City, Utah, 84112, United States
Research Site

Blacktown, 2148, Australia
Research Site

Clayton, 3168, Australia
Research Site

Waratah, 2298, Australia
Research Site

Brussels, 1200, Belgium
Research Site

Edegem, 2650, Belgium
Research Site

Leuven, 3000, Belgium
Research Site

Vancouver, British Columbia, V5Z 4E6, Canada
Research Site

Toronto, Ontario, M5G 1Z5, Canada
Research Site

Marseille, 13385, France
Research Site

Nantes, 44093, France
Research Site

Debrecen, 4032, Hungary
Research Site

Milan, 20132, Italy
Research Site

Milan, 20141, Italy
Research Site

Grafton, 1023, New Zealand
Research Site

Seoul, 03080, South Korea
Research Site

Seoul, 03722, South Korea
Research Site

Seoul, 05505, South Korea
Research Site

Seoul, 06351, South Korea
Research Site

Seoul, 06591, South Korea
Research Site

Barcelona, 08035, Spain
Research Site

Madrid, 28027, Spain
Research Site

Madrid, 28034, Spain
Research Site

Málaga, 29010, Spain
Research Site

Pamplona, 31008, Spain
Research Site

Seville, 41013, Spain
Research Site

London, SW2 6JJ, United Kingdom
Research Site

Sutton, SM2 5PT, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.